Lithium suppresses cell proliferation by interrupting E2F–DNA interaction and subsequently reducing S–phase gene expression in prostate cancer
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lithium is an existing drug for bipolar disorder and its uptake was recently linked to reduced tumor incidence compared to the general population. The major target of lithium action is glycogen synthase kinase 3 (GSK‐3). Since GSK‐3 expression and activation are associated with prostate cancer progression, the anti‐cancer potential of lithium on prostate cancer was investigated in this study. METHODS: Multiple prostate cancer cell lines were treated with lithium chloride (LiCl). Cell proliferation and cell cycle distribution were analysed. DNA replication was determined using BrdU labeling assay. Genome‐wide screening of gene expression was performed using cDNA microarray assay. GSK‐3β gene‐specific silencing was conducted using small interferencing RNA (siRNA) transfection. E2 factor (E2F) transactivation was evaluated using reporter gene assay and E2F–DNA interaction was determined with chromatin‐immunoprecipitation assay (ChIP). RESULTS: LiCl significantly inhibited cell proliferation, which was associated with reduced DNA replication and S‐phase cell cycle arrest. LiCl significantly decreased the expression of multiple DNA replication‐related genes, including cell division cycle 6 (cdc6), cyclin A, cyclin E, and cdc25C, which are regulated by E2F factor during cell cycle. A novel GSK‐3‐specific inhibitor TDZD‐8 and GSK‐3β siRNA also suppressed the expression of these E2F target genes, indicating that LiCl‐induced anti‐cancer effect was associated with GSK‐3β inhibition. Furthermore, LiCl suppressed E2F transactivation by interrupting the interaction of E2F1 factor with its target gene promoter. CONCLUSIONS: These data indicated that LiCl suppresses cancer cell proliferation by disrupting E2F–DNA interaction and subsequent E2F‐mediated gene expression in prostate cancer. Prostate 67: 976–988, 2007. © 2007 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278 · cited 1×
“Recently, we reported that high levels of GSK-3bY216 phosphorylationwas associatedwith aggressive prostate cancers and that GSK-3b activity is required for androgen receptor (AR) transactivation [6], which is a critical determinant in the progression of prostate cancer [7].”
BackgroundGlycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130 · cited 2×
“Furthermore, a recent report showed that GSK-3b inactivation led to a depletion of cyclin D1 expression due to a defect of NFkB pathway in pancreatic cancer cells [39], which is totally opposite to a previous report [37].”
BackgroundResultThe E2F transcriptional network: old acquaintances with new faces
Dimova, D. K., & Dyson, N. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208612 · Cited by 715 · cited 2×
“These DNA replication-related genes are tightly regulated by E2F transcription factors during cell cycle progression [34,35].”
BackgroundHernández, F., Borrell, J., Guaza, C., Avila, J., & Lucas, J. J. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01269.x · Cited by 372
WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases
Ogryzko, V. V., Wong, P., & Howard, B. H. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.8.4877 · Cited by 193
Cited by
Sleire, L., Førde, H. E., Netland, I. A., Leiss, L., Skeie, B. S., & Enger, P. Ø. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.013 · Cited by 329
“Sun et al showed growth inhibitory effects of LiCl through GSK3 inhibition in prostate cancer cell lines and tumor xenografts, due to reduced interaction between the transcription factor E2F and DNA that induce S-phase gene expression (153).”
BackgroundReview of Lithium Effects on Brain and Blood
Young, W. (2009) · Cell Transplantation · doi:10.3727/096368909x471251 · Cited by 287
New drugs are not enough‑drug repositioning in oncology: An update
Armando, R., Mengual G�mez, D., & Gomez, D. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4966 · Cited by 90
Aberrant GSK3β nuclear localization promotes AML growth and drug resistance
Ignatz-Hoover, J. J., Wang, V., Mackowski, N. M., Roe, A. J., Ghansah, I. K., Ueda, M., Lazarus, H. M., de Lima, M., Paietta, E., Fernandez, H., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018016006 · Cited by 27
Metadata
- Authors
- Sun, A., Shanmugam, I., Song, J., Terranova, P. F., Thrasher, J. B., & Li, B.
- Venue
- The Prostate
- Publisher
- Wiley
- Published
- 2007-04-17
- Volume
- 67
- Issue
- 9
- Pages
- 976-988
- ISSN
- 0270-4137 (ISSN-L)
- 1097-0045
- OpenAlex
- W2067671227
- Cited by
- 81
- References
- 5
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lithium suppresses cell proliferation by interrupting E2F–DNA interaction and subsequently reducing S–phase gene expression in prostate cancer. https://app.cochat.ai/papers/10.1002/pros.20586
- The paper
- Sun, A., Shanmugam, I., Song, J., Terranova, P. F., Thrasher, J. B., & Li, B. (2007). Lithium suppresses cell proliferation by interrupting E2F–DNA interaction and subsequently reducing S–phase gene expression in prostate cancer. The Prostate. https://doi.org/10.1002/pros.20586
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.